Study reveals robust memory T-cell responses to SARS-CoV-2 in healthcare workers over 1.5 years post-Omicron, suggesting durable immunity against highly mutated variants.
FDA approves US WorldMeds’ iwilfin for neuroblastoma
Share this article The oral maintenance therapy is intended for high-risk neuroblastoma. Credit: PeopleImages.com – Yuri A / Shutterstock.com. The US Food and Drug Administration